Delivery Order SPE2DB25D3012-SPE2DB26FWVRC
Award Date 10/28/25
Potential Completion Date 11/19/25
Potential Value $48K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency has awarded a delivery order valued at $120,192.80 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of May 15, 2025. The awardee, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed price contract, awarded on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,154.24 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 24, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. Ocrevus is a monoclonal antibody therapeutic used to treat multiple sclerosis,...
- The Defense Logistics Agency has awarded a delivery order valued at $360,578.40 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $72,115.74. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price structure and is scheduled for completion by August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 18, 2025. The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 9, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $120,192.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a non-set-aside competitive award with an ultimate completion date of October 9, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the contract at its corporate office location. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $63,767.62 delivery order to AmerisourceBergen Drug Corp for Ocrevus 300 mg/10 ml vials on September 8, 2025, with completion targeted for September 29, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside arrangement. Ocrevus is a monoclonal antibody used primarily for treating multiple sclerosis, reflecting the pharmaceutical distributor's role in supplying specialized medications to support military and veteran...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...